Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.36%
1,096.72
+3.98
+0.36%
—1,092.741,095.951,103.321,094.72——
SIXC
Communications
SIXC
Communications
SIXC
-0.33%
611.32
-2.04
-0.33%
—613.36613.36613.36609.50——
SIXE
Energy
SIXE
Energy
SIXE
-0.45%
1,171.54
-5.25
-0.45%
—1,176.791,176.521,182.251,166.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.45%
1,747.63
-7.91
-0.45%
—1,755.541,759.231,766.301,746.04——
SIXM
Financials
SIXM
Financials
SIXM
-0.58%
631.49
-3.66
-0.58%
—635.15635.20636.89630.09——
SIXR
Staples
SIXR
Staples
SIXR
+0.23%
849.94
+1.93
+0.23%
—848.01852.52855.78849.58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.09%
218.06
+0.20
+0.09%
—217.86217.86219.52217.86——
SIXT
Technology
SIXT
Technology
SIXT
+3.47%
3,536.03
+118.68
+3.47%
—3,417.353,452.773,536.033,450.39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.91%
905.07
-8.29
-0.91%
—913.36915.10920.43904.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.86%
1,449.86
-12.52
-0.86%
—1,462.381,461.131,464.531,446.02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.30%
2,430.47
+7.33
+0.30%
—2,423.142,428.712,448.692,424.63——
MVR0:FRA
Medivir AB
€0.14
+9.87%
(+0.013) 1D
May 8, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MVR0...
Open
€0.14
High
€0.14
Low
€0.14
Mkt. cap
937.29M
Avg. vol.
11.00
Volume
0.00
52-wk high
€0.26
52-wk low
€0.00
No. of employees
10
News stories
From sources across the web
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List. In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
CEOChristine Lind
Employees10
Founded1988
Headquarters-
SectorBiotechnology
Websitemedivir.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.50M
1.00M
5.51M
1.30M
Cost of goods sold
17.00M
8.10M
10.21M
4.50M
Cost of revenue
17.00M
8.10M
10.21M
4.50M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.10M
5.80M
7.16M
5.50M
Operating expense
7.60M
6.50M
37.66M
6.20M
Total operating expenses
24.60M
14.60M
47.88M
10.70M
Operating income
-23.10M
-13.60M
-42.37M
-9.40M
Other non operating income
-
-
-500.00K
-
EBT including unusual items
-23.30M
-14.60M
-43.20M
-9.40M
EBT excluding unusual items
-23.30M
-14.60M
-43.77M
-9.40M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-200.00K
-
-7.00K
-
Net income
-23.30M
-14.60M
-43.20M
-9.40M
Net profit margin
-1,553.33%
-1,460.00%
-784.60%
-723.08%
Earnings per share
-0.20
-0.13
-
-
Interest and investment income
-
-
41.00K
-
Interest expense
-200.00K
-1.00M
-1.31M
-
Net interest expenses
-200.00K
-1.00M
-1.27M
-
Depreciation and amortization charges
700.00K
700.00K
30.51M
700.00K
EBITDA
-22.40M
-12.90M
-11.87M
-9.38M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer